InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: Inoviorulez post# 1214

Wednesday, 03/08/2017 8:19:39 PM

Wednesday, March 08, 2017 8:19:39 PM

Post# of 2104
I agree that with successful ph2b trials in particular in nash cirrhosis cnat could be trading in triple digits . With extension to other lc etiologies and peak sales in the (tens of) usd billions ( millions of potential patients just in us and eu, little or no competition and a 50/100k per annum price tag) it could be eventually trading in the thousands of usd also considering little or no dilution from now on